Synthetic vaccine nanoparticles target to lymph node triggering enhanced innate and adaptive antitumor immunity

Biomaterials

Volumn 130, Issue , 2017, Pages 56-66

  Kim, Sun Young ^a   Noh, Young Woock ^a   Kang, Tae Heung ^b   Kim, Jung Eun ^a   Kim, Sohyun ^a   Um, Soong Ho ^a   Oh, Doo Byoung ^c   Park, Yeong Min ^b   Lim, Yong Taik ^a  

^a Sungkyunkwan University   (South Korea)

^b Konkuk University School of Medicine   (South Korea)

^c Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

Adjuvant; Cancer immunotherapy; Delivery; Lymph node; Vaccine

Indexed keywords

ACTIVATION ANALYSIS; AMINO ACIDS; ANTIGENS; BODY FLUIDS; CELLS; CYTOLOGY; INTEGRATED CIRCUITS; INTERFERONS; MAMMALS; NANOPARTICLES; PLANTS (BOTANY); T-CELLS; TUMORS;

ADJUVANT; ANTIGEN PRESENTING CELLS; CANCER IMMUNOTHERAPY; DELIVERY; INFLAMMATORY CYTOKINES; LYMPH NODE; SIMULTANEOUS INJECTIONS; TOLL-LIKE RECEPTOR 3;

VACCINES;

ALPHA INTERFERON; BETA INTERFERON; CANCER VACCINE; GAMMA INTERFERON; INTERLEUKIN 6; NANOPARTICLE; OVALBUMIN; POLY(GAMMA GLUTAMIC ACID); POLYGLUTAMIC ACID; POLYINOSINIC POLYCYTIDYLIC ACID; SYNTHETIC VACCINE NANOPARTICLE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; RECOMBINANT VACCINE;

ADAPTIVE IMMUNITY; AMINATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; CANCER IMMUNIZATION; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL EXPANSION; CONTROLLED STUDY; CYTOKINE RELEASE; DISPERSITY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG TARGETING; EXPERIMENTAL NEOPLASM; FEMALE; IMMUNOSTIMULATION; IN VITRO STUDY; INNATE IMMUNITY; LYMPH NODE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; SURFACE PROPERTY; TUMOR IMMUNITY; ZETA POTENTIAL; ADOPTIVE IMMUNOTHERAPY; ANIMAL; C57BL MOUSE; CHEMISTRY; CHICKEN; IMMUNOLOGY; METABOLISM; NEOPLASM; ULTRASTRUCTURE;

ADAPTIVE IMMUNITY; ANIMALS; CANCER VACCINES; CHICKENS; IMMUNITY, INNATE; IMMUNOTHERAPY, ADOPTIVE; LYMPH NODES; MICE, INBRED C57BL; NANOPARTICLES; NEOPLASMS; OVALBUMIN; POLY I-C; VACCINES, SYNTHETIC;

EID: 85016441252     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2017.03.034     Document Type: Article

References (41)

1. [1] Irvine, D.J., Swartz, M.A., Szeto, G.L., Engineering synthetic vaccines using cues from natural immunity. Nat. Mater. 12 (2013), 978–990.
2. [2] Conde, J., Bao, C., Tan, Y., Cui, D., Edelman, E.R., Azevedo, H.S., et al. Dual targeted immunotherapy via in vivo delivery of biohybrid RNAi-peptide nanoparticles to tumor-associated macrophages and cancer cells. Adv. Funct. Mater. 25 (2015), 4183–4194.
3. [3] Moyano, D.F., Liu, Y., Peer, D., Rotello, V.M., Modulation of immune response using engineered nanoparticle surfaces. Small 12 (2015), 76–82.
4. [4] Dobrovolskaia, M.A., McNeil, S.E., Immunological properties of engineered nanomaterials. Nat. Nanotechnol. 2 (2007), 469–478.
5. [5] Hubbell, J.A., Thomas, S.N., Swartz, M.A., Materials engineering for immunomodulation. Nature 462 (2009), 449–460.
6. [6] Noh, Y.W., Hong, J.H., Shim, S.M., Park, H.S., Bae, H.H., Ryu, E.K., et al. Polymer nanomicelles for efficient mucus delivery and antigen-specific high mucosal immunity. Angew. Chem. 125 (2013), 7838–7843.
7. [7] Naahidi, S., Jafari, M., Edalat, F., Raymond, K., Khademhosseini, A., Chen, P., Biocompatibility of engineered nanoparticles for drug delivery. J. Control. Release 166 (2013), 182–194.
8. [8] Zhou, Q., Zhang, Y., Du, J., Li, Y., Zhou, Y., Fu, Q., et al. Different-sized gold nanoparticle activator/antigen increases dendritic cells accumulation in liver-draining lymph nodes and CD8+ T cell responses. ACS Nano 10 (2016), 2678–2692.
9. [9] Wu, X., He, C., Wu, Y., Chen, X., Cheng, J., Nanogel-incorporated physical and chemical hybrid gels for highly effective chemo–protein combination therapy. Adv. Funct. Mater. 25 (2015), 6744–6755.
10. [10] Smith, D.M., Simon, J.K., Baker, J.R. Jr., Applications of nanotechnology for immunology. Nat. Rev. Immunol. 13 (2013), 592–605.
11. [11] Randolph, G.J., Angeli, V., Swartz, M.A., Dendritic-cell trafficking to lymph nodes through lymphatic vessels. Nat. Rev. Immunol. 5 (2005), 617–628.
12. [12] Bousso, P., T-cell activation by dendritic cells in the lymph node: lessons from the movies. Nat. Rev. Immunol. 8 (2008), 675–684.
13. [13] Reddy, S.T., van der Vlies, A.J., Simeoni, E., Angeli, V., Randolph, G.J., O'Neil, C.P., et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat. Biotechnol. 25 (2007), 1159–1164.
14. [14] Reddy, S.T., Rehor, A., Schmoekel, H.G., Hubbell, J.A., Swartz, M.A., In vivo targeting of dendritic cells in lymph nodes with poly (propylene sulfide) nanoparticles. J. Control Release 112 (2006), 26–34.
15. [15] Noh, Y.-W., Kong, S.-H., Choi, D.-Y., Park, H.S., Yang, H.-K., Lee, H.-J., et al. Near-infrared emitting polymer nanogels for efficient sentinel lymph node mapping. ACS Nano 6 (2012), 7820–7831.
16. [16] Liu, H., Moynihan, K.D., Zheng, Y., Szeto, G.L., Li, A.V., Huang, B., et al. Structure-based programming of lymph-node targeting in molecular vaccines. Nature 507 (2014), 519–522.
17. [17] De Koker, S., Cui, J., Vanparijs, N., Albertazzi, L., Grooten, J., Caruso, F., et al. Engineering polymer hydrogel nanoparticles for lymph node-targeted delivery. Angew. Chem. Int. Ed. 55 (2016), 1334–1339.
18. [18] Jewell, C.M., López, S.C.B., Irvine, D.J., In situ engineering of the lymph node microenvironment via intranodal injection of adjuvant-releasing polymer particles. Proc. Natl. Acad. Sci. 108 (2011), 15745–15750.
19. [19] Ammi, R., De Waele, J., Willemen, Y., Van Brussel, I., Schrijvers, D.M., Lion, E., et al. Poly (I: C) as cancer vaccine adjuvant: knocking on the door of medical breakthroughs. Pharmacol. Ther. 146 (2015), 120–131.
20. [20] DeMuth, P.C., Garcia-Beltran, W.F., Ai-Ling, M.L., Hammond, P.T., Irvine, D.J., Composite dissolving microneedles for coordinated control of antigen and adjuvant delivery kinetics in transcutaneous vaccination. Adv. Funct. Mater. 23 (2013), 161–172.
21. [21] Hafner, A.M., Corthésy, B., Merkle, H.P., Particulate formulations for the delivery of poly (I: C) as vaccine adjuvant. Adv. Drug Del Rev. 65 (2013), 1386–1399.
22. [22] Noh, Y.-W., Jang, Y.-S., Ahn, K.-J., Lim, Y.T., Chung, B.H., Simultaneous in vivo tracking of dendritic cells and priming of an antigen-specific immune response. Biomaterials 32 (2011), 6254–6263.
23. [23] Sung, M.H., Park, C., Kim, C.J., Poo, H., Soda, K., Ashiuchi, M., Natural and edible biopolymer poly-γ-glutamic acid: synthesis, production, and applications. Chem. Rec. 5 (2005), 352–366.
24. [24] Colombo, M.P., Trinchieri, G., Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 13 (2002), 155–168.
25. [25] Matsumoto, M., Tatematsu, M., Nishikawa, F., Azuma, M., Ishii, N., Morii-Sakai, A., et al. Defined TLR3-specific adjuvant that induces NK and CTL activation without significant cytokine production in vivo. Nat. Commun., 6, 2015, 2680.
26. [26] Conforti, R., Ma, Y., Morel, Y., Paturel, C., Terme, M., Viaud, S., et al. Opposing effects of toll-like receptor (TLR3) signaling in tumors can be therapeutically uncoupled to optimize the anticancer efficacy of TLR3 ligands. Cancer Res. 70 (2010), 490–500.
27. [27] Seya, T., Shime, H., Takeda, Y., Tatematsu, M., Takashima, K., Matsumoto, M., Adjuvant for vaccine immunotherapy of cancer–focusing on Toll-like receptor 2 and 3 agonists for safely enhancing antitumor immunity. Cancer Sci. 106 (2015), 1659–1668.
28. [28] Tel, J., Sittig, S.P., Blom, R.A., Cruz, L.J., Schreibelt, G., Figdor, C.G., et al. Targeting uptake receptors on human plasmacytoid dendritic cells triggers antigen cross-presentation and robust type I IFN secretion. J. Immunol. 191 (2013), 5005–5012.
29. [29] Kadowaki, N., Antonenko, S., Liu, Y.-J., Distinct CpG DNA and polyinosinic-polycytidylic acid double-stranded RNA, respectively, stimulate CD11c− type 2 dendritic cell precursors and CD11c+ dendritic cells to produce type I IFN. J. Immunol. 166 (2001), 2291–2295.
30. [30] Le Bon, A., Etchart, N., Rossmann, C., Ashton, M., Hou, S., Gewert, D., et al. Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat. Immunol. 4 (2003), 1009–1015.
31. [31] Kranz, L.M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K.C., et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature 534 (2016), 396–401.
32. [32] Miyashita, A., Fukushima, S., Nakahara, S., Kubo, Y., Tokuzumi, A., Yamashita, J., et al. Immunotherapy against metastatic melanoma with human iPS cell–derived myeloid cell lines producing type I interferons. Cancer Immunol. Res. 4 (2015), 248–258.
33. [33] Kreutz, M., Tacken, P.J., Figdor, C.G., Targeting dendritic cells—why bother?. Blood 121 (2013), 2836–2844.
34. [34] Luo, Z., Wang, C., Yi, H., Li, P., Pan, H., Liu, L., et al. Nanovaccine loaded with poly I: C and STAT3 siRNA robustly elicits anti-tumor immune responses through modulating tumor-associated dendritic cells in vivo. Biomaterials 38 (2015), 50–60.
35. [35] Rosalia, R.A., Cruz, L.J., van Duikeren, S., Tromp, A.T., Silva, A.L., Jiskoot, W., et al. CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses. Biomaterials 40 (2015), 88–97.
36. [36] Tincer, G., Yerlikaya, S., Yagci, F.C., Kahraman, T., Atanur, O.M., Erbatur, O., et al. Immunostimulatory activity of polysaccharide–poly (I: C) nanoparticles. Biomaterials 32 (2011), 4275–4282.
37. [37] Ebihara, T., Azuma, M., Oshiumi, H., Kasamatsu, J., Iwabuchi, K., Matsumoto, K., et al. Identification of a polyI: C-inducible membrane protein that participates in dendritic cell–mediated natural killer cell activation. J. Exp. Med. 207 (2010), 2675–2687.
38. [38] Akazawa, T., Ebihara, T., Okuno, M., Okuda, Y., Shingai, M., Tsujimura, K., et al. Antitumor NK activation induced by the Toll-like receptor 3-TICAM-1 (TRIF) pathway in myeloid dendritic cells. Proc. Natl. Acad. Sci. 104 (2007), 252–257.
39. [39] Klebanoff, C.A., Gattinoni, L., Restifo, N.P., CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol. Rev. 211 (2006), 214–224.
40. [40] Lee, I.H., Kwon, H.K., An, S., Kim, D., Kim, S., Yu, M.K., et al. Imageable antigen-presenting gold nanoparticle vaccines for effective cancer immunotherapy in vivo. Angew. Chem. Int. Ed. 51 (2012), 8800–8805.
41. [41] Liu, H., Kwong, B., Irvine, D.J., Membrane anchored immunostimulatory oligonucleotides for in vivo cell modification and localized immunotherapy. Angew. Chem. Int. Ed. 123 (2011), 7190–7193.